Research In Riskycad


Coronary artery disease (CAD), also known as coronary heart disease (CHD) is the main cause of death and morbidity in the western world and is projected to be the number one killer globally by 2020. In the European Union, it accounts for nearly 1 million deaths per year, with as many as 1 in 5 men and women dying from CAD and as many as 1 in 2 men or women experiencing a cardiac event during lifetime.


RiskyCAD has been set with the aim to identify high risk asymptomatic patients and improve primary prevention of CAD by developing novel therapeutics and tailoring treatment to best match the individual patient’s profile.

Key Cohorts

The main clinical cohorts that will be used by the Consortium include the LURIC and the COROGENE studies.

Key Strengths and Technologies

1. Clinical and clinic-pathological cohorts, 2. iPS cell technology, 3. High throughput miRNA screening, 4. Lipidomics, 5. Computational approaches to ‘personalized’ medicine, 6. Proof-of-concept Cluster, 7. Translational Cluster and direct pathway to commercialization.

Latest News

View All